DeCure for Epidermolysis bullosa simplex 1B, generalized intermediate
DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for epidermolysis bullosa simplex 1B, generalized intermediate — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEpidermolysis bullosa simplex 1B, generalized intermediate maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for epidermolysis bullosa simplex 1b, generalized intermediate is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
keratin 5 (KRT5) — KRT5 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3TNU · 3.005 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Mutations in EXPH5 cause a rare autosomal recessive subtype of epidermolysis bullosa simplex. In one reported family, a 9-year-old boy with consanguineous Pakistani parents had skin fragility from birth with scattered vesicles and bullae up to 1–2 cm on limbs and trunk, worsened by hot weather. Individual blisters healed within 1–2 weeks leaving postinflammatory hypopigmentation. His blistering tendency persisted but improved with age. His 2-year-old brother had similar symptoms. Their father, whose own parents were first cousins, had similar skin fragility as a child that resolved completely by age 10. The father declined to participate in the study.
Epidermolysis bullosa simplex is a rare autosomal dominant genetic condition in which bullous lesions larger than 0.5 cm appear on skin exposed to mechanical friction or minor trauma. Prevention begins with family and patient education, and infants require greater environmental control. Treatment plans are tailored to the severity and extent of skin involvement. No drug therapy is described in these abstracts.
A 2025 review notes that hereditary epidermolysis bullosa involves mutations in at least 20 different genes, leading to conformational changes or absence of cytoskeletal, cell-matrix, or cell adhesion proteins in the skin. Four basic types are distinguished: simplex, junctional, dystrophic, and Kindler syndrome, with at least 30 clinical subtypes. The review does not report any new drug treatment results.
No controlled trial data, no quantitative outcomes such as survival or response rates, and no drug interventions are reported in these abstracts. What is missing is any funded clinical trial testing a repurposed drug, any patient stratification by genotype, and any prospective evidence that a specific compound alters blister frequency or healing time in epidermolysis bullosa simplex.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Journal of Dermatology · 2015 · 10 citations
Mutations in <i>EXPH5</i> underlie a rare subtype of autosomal recessive epidermolysis bullosa simplex
AbstractFunding sources: This study received funding/support from the National Institute for Health Research Biomedical Research Centre based at Guy's and St Thomas’ NHS Foundation Trust and King's College London. Conflicts of interest: none declared. Dear Editor, Epidermolysis bullosa simplex (EBS) is a heterogeneous disorder with mutations in at least nine different genes underlying various autosomal dominant and recessive subtypes thereof.1 Making an accurate clinical and laboratory diagnosis in some of the less common forms of EBS can be challenging. A 9‐year‐old boy with first‐cousin Pakistani parents presented with skin fragility from birth. He had scattered vesicles and bullae up to 1–2 cm in size on the limbs and trunk (Fig. 1a, b). Blistering was made worse by hot weather. Individual blisters healed within 1–2 weeks, leaving postinflammatory hypopigmentation. His blistering tendency persisted but ameliorated with age. Hair, teeth, nails and mucosae were normal. His 2‐year‐old brother had similar symptoms and signs from birth. Of note, the father of both children, whose parents were also first cousins, had similar skin fragility as a child that resolved completely by 10 years of age. The pattern of inheritance was consistent with autosomal recessive transmission, with possible pseudodominant inheritance, given the father's history of blistering. Unfortunately, the father declined to participate in the study and was not available for further evaluation.
Journal of the Dermatology Nurses’ Association · 2022 · 1 citations
Epidermolysis Bullosa Simplex
AbstractABSTRACT Epidermolysis bullosa simplex (EBS) is a rare autosomal dominant, genetic condition where bullous lesions, larger than 0.5 cm, affect an area of the skin that is exposed to mechanical friction or minor trauma. Prevention of the bullous lesions starts with family and patient education, with infants requiring greater care and control of their environment. Every individual with EBS will have a treatment plan specifically tailored to the severity and extent of skin involvement. This article provides a comprehensive overview of EBS, including diagnostic approach, preventative considerations, and current treatments.
Slovenska pediatrija revija pediatrov Slovenije in specialistov šolske ter visokošolske medicine Slovenije · 2025 · 0 citations · open access
EPIDERMOLYSIS BULLOSA HEREDITARIA: A DERMATOLOGIST‘S PERSPECTIVE AND NEWLY TREATMENT APPROACHES
AbstractIzvleekDedna bulozna epidermoliza je genetsko povzroena bolezen krhkosti koe.Doslej so bile identificirane mutacije, ki vkljuujejo vsaj 20 razlinih genov s posledino konformacijsko spremenjenostjo ali odsotnostjo beljakovin citoskeleta, celinega matriksa ali beljakovin medceline adhezije v koi.Na osnovi genetsko povzroenih molekularnih nepravilnosti in zato nastalih razslojevanj konega tkiva razlikujemo 4 osnovne tipe bolezni: simpleks, junkcijsko in distrofino dedno bulozno epidermolizo ter Kindlerjev sindrom; v sklopu osnovnih tipov poznamo vsaj 30 klinino razlinih podtipov bolezni.Pri tejih oblikah dednih buloznih epidermoliz se lahko pojavljajo zapleti na koi, sluznicah ali konih adne-
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
